Autopsy Services and Emergency Preparedness of a Tertiary Academic Hospital Mortuary for the COVID-19 Public Health Emergency: The Yale Plan

Pathology Autopsy and Mortuary Services have been front and center in the severe acute respiratory syndrome coronavirus 2 (SARS-Co-V-2) pandemic. The sheer number of fatalities from the pandemic have been unlike any other in recent memory and needed the rapid creation of new protocols and paradigms to manage the situation. This required rapidly escalating mortuary capacity to manage the increased fatalities from the pandemic with the establishment of lines of communication and networking with governmental entities, institution of new policies for patient flow, and implementation of worker infection control and well-being plans. Autopsies also assumed a crucial role, both to provide insight into the pathomechanisms of a novel disease and to allow tissue retrieval necessary to power research directed towards finding a vaccine. We here outline the plan adopted by the Yale Autopsy and Mortuary Services, in alignment with the institutional mission of high-quality patient care, education, research and health care worker safety and well-being, as the Corona Virus Disease of 2019 (COVID-19) pandemic surged in Connecticut. In the early response phase, ensuring sufficient mortuary capacity necessarily took center stage. As we enter the recovery and plateau phase of the pandemic, setting up a process for a rapid and safe autopsy, that will meet educational and research needs while ensuring the safety of our workforce is being implemented.
Source: Advances in Anatomic Pathology - Category: Pathology Tags: Review Articles Source Type: research

Related Links:

The global pandemic of COVID-19 disease caused by infection with the SARS-CoV-2 coronavirus, has produced an urgent requirement and search for improved treatments while effective vaccines are developed. A strategy for improved drug therapy is to increase levels of endogenous reactive metabolites for selective toxicity to SARS-CoV-2 by preferential damage to the viral proteome. Key reactive metabolites producing major quantitative damage to the proteome in physiological systems are: reactive oxygen species (ROS) and the reactive glycating agent methylglyoxal (MG); cysteine residues and arginine residues are their most susce...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Kizzmekia Corbett joins TWiV to review her career and her work on respiratory syncytial virus, influenza virus, and coronaviruses and coronavirus vaccines, including her role in development and testing of a spike-encoding mRNA vaccine, and then we review the Nobel Prize for discovery of hepatitis C virus. Click arrow to playDownload TWiV 670 (76 MB .mp3, […]
Source: virology blog - Category: Virology Authors: Tags: This Week in Virology coronavirus COVID-19 influenza virus mRNA-1273 pandemic prefusion conformation respiratory syncytial virus SARS-CoV-2 spike vaccine viral viruses Source Type: blogs
(Johns Hopkins Medicine) While the world waits eagerly for a safe and effective vaccine to prevent infections from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus behind the COVID-19 pandemic, researchers also are focusing on better understanding how SARS-CoV-2 attacks the body in the search for other means of stopping its devastating impact.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
TriPla Regimen: A new treatment approach for patients with neovascular age-related macular degeneration in the COVID-19 "era". Eur J Ophthalmol. 2020 Oct 07;:1120672120963448 Authors: Sacconi R, Borrelli E, Vella G, Querques L, Prascina F, Zucchiatti I, Bandello F, Querques G Abstract In the last months, a rapidly increasing number of people have been infected with severe acute respiratory syndrome coronavirus 2, the virus causing coronavirus disease 2019 (COVID-19). Due to the risk of cross-infections, the number of visits and injections was dramatically reduced in the last months, and the ...
Source: European Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Eur J Ophthalmol Source Type: research
This article describes the scope of the COVID-19 project; some of the content captured from websites, blogs, and social media; collecting criteria and methods; and related COVID-19 collecting efforts by other groups. The growing collection-2,500 items as of June 30, 2020-chronicles the many facets of the pandemic: epidemiology; vaccine and drug research; disease control measures and resistance to them; effects of the pandemic on health care institutions and workers, education, commerce, and many aspects of social life; effects for especially vulnerable groups; role of health disparities in infection and mortality; and reco...
Source: Journal of the Medical Library Association : JMLA - Category: Databases & Libraries Tags: J Med Libr Assoc Source Type: research
Purpose of review The Coronavirus Disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global health threat associated with major socioeconomic disruptions. Understanding on the transmission characteristics of SARS-CoV-2 is crucial for optimizing preventive strategies. Recent findings SARS-CoV-2 can be transmitted efficiently between persons through respiratory droplets and direct and indirect contact. The significance of airborne droplet nuclei in SARS-CoV-2 transmission in the community setting is less clear. SARS-CoV-2 RNA and live viral particles ma...
Source: Current Opinion in HIV and AIDS - Category: Infectious Diseases Tags: COVID19: Edited by Zhiwei Chen and Linqui Zhang Source Type: research
Scientists worldwide are racing to develop effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic. An important and perhaps underappreciated aspect of this endeavor is ensuring that the vaccines being developed confer immunity to all viral lineages in the global population. Toward...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Commentaries Source Type: research
Since December 2019, the coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has spread worldwide, affecting millions of people and leaving hundreds of thousands dead, mostly older adults. Recently, the five main geriatric journals in the United States have joined together to produce a common text denouncing the ageism that manifested itself during the first wave of the pandemic. This text proposes four recommendations: 1) to make clinical research more inclusive for all ages, 2) to involve geriatricians and gerontologists in institutional decisions, 3) to inform policy and funding by taking into account the specific ...
Source: Maturitas - Category: Primary Care Authors: Source Type: research
Abstract The novel human coronavirus-2 (HCoV-2), called SARS-CoV-2, is the causative agent of Coronavirus Induced Disease (COVID-19) and has spread causing a global pandemic. Currently, there is no vaccine to prevent infection nor any approved drug for the treatment. The development of a new drug is time-consuming and cannot be relied on as a solution in combatting the immediate global challenge. In such a situation, the drug repurposing becomes an attractive solution to identify the potential of COVID-19 treatment by existing drugs, which are approved for other indications. Here, we review the potential use of ra...
Source: Chemico-Biological Interactions - Category: Molecular Biology Authors: Tags: Chem Biol Interact Source Type: research
AbstractThe ongoing pandemic of Coronavirus disease 19 (COVID-19) is caused by a newly discovered β Coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). How long the adaptive immunity triggered by SARS-CoV-2 can last is of critical clinical relevance in assessing the probability of second infection and efficacy of vaccination. Here we examined, using ELISA, the IgG an tibodies in serum specimens collected from 17 COVID-19 patients at 6–7 months after diagnosis and the results were compared to those from cases investigated 2 weeks to 2 months post-infection. All samples were positive fo...
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
More News: Academia | Coronavirus | COVID-19 | Education | Emergency Medicine | Health Management | Hospitals | International Medicine & Public Health | Pandemics | Pathology | Respiratory Medicine | SARS | Universities & Medical Training | Vaccines | Yale